Key Takeaways

  • BlackRock, Inc. filed a Form 8.3 RNS (RNS Number 7165I) on Beazley plc (LSE: BEZ), covering dealings on 16 June 2026 and published 17 June 2026.
  • BlackRock's total disclosed interest was 51,460,730 shares, equal to 8.55% of Beazley's 5p ordinary shares, with no short position (0.00%).
  • Directly owned or controlled securities totalled 37,855,338 shares (6.29%), with cash-settled derivatives adding 13,605,392 reference shares (2.26%).
  • On the day, BlackRock bought 14,120 shares and sold 2,221 shares, both at GBP 12.8400.
  • The disclosure lands during Beazley's offer period tied to Zurich Insurance Group's recommended all-cash scheme at 1,310p per share plus a 25p dividend.

BlackRock's Form 8.3 Sheds Light on Beazley Ownership

BlackRock, Inc. has filed a Form 8.3 disclosure on specialist insurer Beazley plc (LSE: BEZ), revealing one of the larger institutional positions in the Lloyd's of London-focused group as it works towards a takeover by Zurich Insurance Group. The disclosure was carried over the Regulatory News Service under RNS Number 7165I, dated 17 June 2026 and relating to dealings on 16 June 2026.

Form 8.3 filings are mandatory under Rule 8.3 of the UK Takeover Code for any party holding 1% or more of a company that is in an offer period. With Beazley firmly in play, BlackRock's disclosure gives the market a clear view of how a major holder is positioned as the bid timetable progresses.

BlackRock confirmed the form relates to Beazley plc as the offeree and that it was not disclosing in respect of any other party to the offer.

The Numbers: An 8.55% Interest, No Short

The standout figure is a total interest of 51,460,730 Beazley shares, equal to 8.55% of the 5p ordinary share class, with the short-position column reported at 0.00%, an entirely long book.

Within that total, BlackRock disclosed 37,855,338 relevant securities owned and/or controlled (6.29%) and cash-settled derivatives referencing 13,605,392 shares (2.26%). The firm noted it does not hold voting authority over 1,894,601 of these shares, while investment discretion is retained.

On dealings, the disclosure shows a purchase of 14,120 shares and a sale of 2,221 shares, both executed at GBP 12.8400. No cash-settled derivative dealings or other transactions were recorded for the day, and BlackRock disclosed no indemnity or option arrangements.

The Discloser and the Zurich Takeover Backdrop

As a global asset manager, BlackRock holds Beazley across a range of index and active strategies, and an interest exceeding 8% places it among the company's most significant holders. In a scheme of arrangement, where a high acceptance threshold is required, the stance of such investors carries real weight.

Beazley entered an offer period ahead of Zurich Insurance Group's recommended all-cash offer, with a Rule 2.7 firm-offer announcement made on 2 March 2026. Revised terms put 1,310p per share in cash plus a 25p dividend on the table, valuing Beazley at approximately GBP 8bn, a premium of roughly 59.8% to the 16 January closing price. The acquisition is being implemented by a scheme of arrangement.

An interest of 8.55% from a single manager is therefore material to the arithmetic of that scheme, even though the disclosure itself takes no position on the merits of the deal.

Why This RNS Matters

Form 8.3 disclosures are a core part of the transparency machinery during UK takeovers, showing whether substantial holders are adding to, holding or reducing their exposure as a bid proceeds. BlackRock's predominantly long, unhedged position in Beazley is a useful signal of how concentrated ownership is among large institutions.

Because Zurich's offer is all-cash and recommended, the gap between Beazley's market price and the 1,310p-plus-dividend value reflects the market's confidence in completion. The disposition of major holders such as BlackRock can inform both that spread and the eventual scheme vote.

What Investors Should Watch Next

Investors should look for subsequent Form 8.3 filings from BlackRock and other 1%-plus holders to see whether positions trend higher or lower as the scheme advances. Any sizeable change from the current ~8.55% level would be notable.

Key milestones include the scheme document, the court-convened shareholder meeting, court sanction and any insurance-sector regulatory approvals. Watching the share price relative to the offer terms will indicate whether the market views completion as highly likely.